Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Hidetoshi Kawaguchi"'
Autor:
Misato Masuyama, Norikazu Masuda, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 17718-17730 (2023)
Abstract Background The role of endocrine therapy in the treatment of patients in a postmenopausal hormonal state and with estrogen receptor (ER)‐positive, human epidermal growth factor receptor 2 (HER2)‐positive advanced or metastatic breast can
Externí odkaz:
https://doaj.org/article/caeec8fc425642ad8dfd47e91b38c921
Publikováno v:
IEEE Access, Vol 10, Pp 105713-105725 (2022)
As intrusion detection and prevention systems (IDPSs) grow in importance, the cost of managing signatures, which are pattern files of malicious communications, continues to increase. To ensure the optimal operation of an IDPS, network security expert
Externí odkaz:
https://doaj.org/article/5c9cd288be024cb3bf871ea377d07aba
Autor:
Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Publikováno v:
Japanese Journal of Clinical Oncology. 52:545-553
Background The Safari study (UMIN000015168) was a retrospective, multicenter study in which 1072 consecutive cases of estrogen receptor-positive advanced breast cancer treated using 500 mg fulvestrant were registered. We previously reported the relat
Publikováno v:
IEEE Access. 10:105713-105725
Autor:
Kaho Utsunomiya, Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Publikováno v:
Cancer Research. 83:P2-03
Background: Only old evidence exist to back up the use of medroxyprogesterone acetate (MPA) in endocrine therapy. Therefore, this study aimed to explore the factors that influence the time to treatment failure (TTF) of MPA in real world settings as l
Autor:
Hidetoshi Kawaguchi, Yutaka Yamamoto, Shigehira Saji, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Toshinari Yamashita, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Publikováno v:
Japanese journal of clinical oncology.
BackgroundOnly old evidence exists to back up the use of medroxyprogesterone acetate. Therefore, this study aimed to explore the factors that influence the time to treatment failure of medroxyprogesterone acetate in real-world settings as late-line t
Publikováno v:
Steel Construction. 14:55-63
Autor:
Nobutaka Sato, Yoshihiko Komohara, Toru Beppu, Hideaki Yuki, Hideaki Miyamoto, Hidetoshi Kawaguchi, Shinichi Akahoshi, Toshihiko Motohara, Koichi Kinoshita, Eri Oda, Kensuke Yamamura
Publikováno v:
Anticancer Research. 40:6465-6471
Aim To assess the utility of the perioperative use of direct oral anticoagulants for patients with hepatocellular carcinoma (HCC) with cancer-associated thrombosis. Case report An 83-year-old woman was admitted with a solitary HCC (10-cm diameter), a
Autor:
Masahiro Kitada, Hidetoshi Kawaguchi, Masaya Hattori, Satoshi Morita, Shinji Ohno, Yoshie Hasegawa, Toshinari Yamashita, Masahiro Kashiwaba, Kazuhiro Yanagihara, Teru Kawasoe, Norikazu Masuda, Tetsuhiro Yoshinami, Kazutaka Narui, Hiroko Bando, Nobuki Matsunami, Rikiya Nakamura, Hiroshi Yano, Masakazu Toi, Takeshi Nagashima
Publikováno v:
Investigational New Drugs
SummaryPurpose To date, it is not clear which anticancer agent is useful in combination with trastuzumab and pertuzumab As the first and second selective regimens for advanced or metastatic breast cancer (AMBC), this multicenter, open-label, phase II
Autor:
Hiroyasu Yamashiro, Koichiro Tsugawa, Kojiro Mashino, Tatsuya Toyama, Tomomi Fujisawa, Shoichiro Ohtani, Uhi Toh, Rikiya Nakamura, Masakazu Toi, Takahiro Nakayama, Naoto Kondo, Masahiro Kashiwaba, Shinji Ohno, Yutaka Yamamoto, Yuichi Tanino, Takashi Ishikawa, Hidetoshi Kawaguchi, Toshimi Takano, Masato Takahashi, Satoshi Morita
Publikováno v:
Breast Cancer (Tokyo, Japan)
Purpose To investigate the effectiveness and safety of bevacizumab–paclitaxel combination therapy as first- or second-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer in daily clinical practice. Methods In this prosp